Nina Tunariu
Overview
Explore the profile of Nina Tunariu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
7511
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Candito A, Holbrey R, Ribeiro A, Messiou C, Tunariu N, Koh D, et al.
Bioengineering (Basel)
. 2024 Feb;
11(2).
PMID: 38391616
Background: Whole-Body Diffusion-Weighted Imaging (WBDWI) is an established technique for staging and evaluating treatment response in patients with multiple myeloma (MM) and advanced prostate cancer (APC). However, WBDWI scans show...
12.
Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne J, et al.
Clin Cancer Res
. 2024 Feb;
30(10):2140-2159.
PMID: 38376926
Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use...
13.
Donners R, Figueiredo I, Westaby D, Koh D, Tunariu N, Carreira S, et al.
Cancer Imaging
. 2023 Dec;
23(1):121.
PMID: 38102655
Background: Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study's objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm to facilitate target lesion...
14.
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al.
Nature
. 2023 Oct;
623(7989):1053-1061.
PMID: 37844613
Inflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and...
15.
Parker C, Tunariu N, Tovey H, Alonzi R, Blackledge M, Cook G, et al.
JNCI Cancer Spectr
. 2023 Oct;
7(6).
PMID: 37788117
Background: Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation Criteria in Solid...
16.
Castagnoli F, Donners R, Tunariu N, Messiou C, Koh D
Br J Radiol
. 2023 Sep;
96(1152):20230240.
PMID: 37750943
Objectives: To compare relative fat fraction (rFF) of active bone lesions from breast, prostate and myeloma malignancies and normal bone marrow; to assess its inter-reader agreement. Methods: Patients with breast...
17.
Oprea-Lager D, MacLennan S, Bjartell A, Briganti A, Burger I, de Jong I, et al.
Eur Urol
. 2023 Sep;
85(1):49-60.
PMID: 37743194
Background: In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA radioligand therapy, integration of advanced imaging in nomogram-based decision-making,...
18.
Donners R, Candito A, Blackledge M, Rata M, Messiou C, Koh D, et al.
Br J Radiol
. 2023 Sep;
96(1151):20230378.
PMID: 37660399
Objectives: To assess the repeatability of quantitative multiparametric whole-body MRI (mpWB-MRI) parameters in advanced prostate cancer (APC) bone metastases. Methods: 1.5T MRI was performed twice on the same day in...
19.
Neeb A, Figueiredo I, Gurel B, Nava Rodrigues D, Rekowski J, Riisnaes R, et al.
Lab Invest
. 2023 Aug;
103(11):100245.
PMID: 37652207
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating the clinical...
20.
Donners R, Tunariu N, Tovey H, Hall E, Chua S, Cook G, et al.
Eur Radiol
. 2023 Aug;
34(2):1146-1154.
PMID: 37615760
Objectives: To investigate whether baseline 18F-sodium fluoride (NaF) and 18F-choline PET activity is associated with metastatic castration-resistant prostate cancer (mCRPC) global and individual bone metastases' DWI MR imaging response to...